Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
Open Access
- 21 April 2017
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 6 (6) , 1341-1352
Abstract
Catechol‐O‐methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O‐methylation. Tolcapone, a drug commonly used in the treatment of Parkinson's disease, is a potent inhibitor of COMT and previous studies indicate that Tolcapone increases the bioavailability of dopamine in cells. In this study, we demonstrate that Tolcapone kills neuroblastoma (NB) cells in preclinical models by inhibition of COMT. Treating four established NB cells lines (SMS‐KCNR, SH‐SY5Y, BE(2)‐C, CHLA‐90) and two primary NB cell lines with Tolcapone for 48 h decreased cell viability in a dose‐dependent manner, with IncuCyte imaging and Western blotting indicating that cell death was due to caspase‐3‐mediated apoptosis. Tolcapone also increased ROS while simultaneously decreasing ATP‐per‐cell in NB cells. Additionally, COMT was inhibited by siRNA in NB cells and showed similar increases in apoptotic markers compared to Tolcapone. In vivo xenograft models displayed inhibition of tumor growth and a significant decrease in time‐to‐event in mice treated with Tolcapone compared to untreated mice. These results indicate that Tolcapone is cytotoxic to neuroblastoma cells and invite further studies into Tolcapone as a promising novel therapy for the treatment of neuroblastoma.Keywords
Funding Information
- Beat NB Foundation
- Dick and Betsy DeVos Foundation
- Meryl and Charles Witmer Foundation
- Max's Ring of Fire Foundation
- Ezra Foundation
- Melina's White Light Foundation
- Owen Moscone Foundation
- Richard and Ethie Haworth Foundation
This publication has 33 references indexed in Scilit:
- Orientation and Cellular Distribution of Membrane-bound Catechol-O-methyltransferase in Cortical NeuronsJournal of Biological Chemistry, 2011
- New therapeutic targets for the treatment of high‐risk neuroblastomaJournal of Cellular Biochemistry, 2009
- Hypoxia, HIF1 and glucose metabolism in the solid tumourNature Reviews Cancer, 2008
- Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's DiseaseCNS Neuroscience & Therapeutics, 2008
- Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's DiseaseCNS Neuroscience & Therapeutics, 2008
- Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: Implications for Parkinson diseaseNeurobiology of Disease, 2008
- TolcaponeClinical Neuropharmacology, 2007
- Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass LesionsAmerican Journal of Ophthalmology, 2006
- Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cellsNeuropharmacology, 2004
- Pathogenesis of parkinson's disease: dopamine, vesicles and α-synucleinNature Reviews Neuroscience, 2002